Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome

Modern Pathology

Volumn 18, Issue 7, 2005, Pages 877-885

  Oudejans, Joost J ^a   Harijadi, Ahemd ^b   Cillessen, Saskia A G M ^a   Busson, Pierre ^c   Tan, I Bing ^d   Dukers, Danny F ^a   Vos, Wim ^a   Hariwiyanto, Bambang ^b   Middeldorp, Jaap ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Apoptosis; bcl 2; Caspase; Nasopharyngeal carcinoma; Prognosis; XIAP

Indexed keywords

CASPASE 3; PROCASPASE 3; PROTEIN BCL 2; PROTEIN P53; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; APOPTOSIS; ARTICLE; BIOPSY; CANCER STAGING; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FATALITY; FEMALE; HUMAN; HUMAN CELL; MALE; NASOPHARYNX CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOPSY; CASPASE 3; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; ETOPOSIDE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 23044475504     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800398     Document Type: Article

References (46)

1. Spano JP, Busson P, Atlan D, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003;39: 2121-2135.
2. Teo PM, Chan AT. Treatment strategy and clinical experience. Semin Cancer Biol 2002;12:497-504.
3. Fandi A, Cvitkovic E. Biology and treatment of nasopharyngeal cancer. Curr Opin Oncol 1995;7:255-263.
4. Friesen C, Herr I, Krammer PH, et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996;2:574-577.
5. Los M, Herr I, Friesen C, et al. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997;90:3118-3129.
6. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ 1999;6:471-480.
7. Belka C, Marini P, Lepple-Wienhues A, et al. The tyrosine kinase lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene 1999;18:4983-4992.
8. Wesselborg S, Engels IH, Rossmann E, et al. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 1999;93:3053-3063.
9. Tan G, Heqing L, Jiangbo C, et al. Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. Int J Cancer 2002;97:168-172.
10. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999;17:781-828.
11. Jurgensmeier JM, Xie Z, Deveraux Q, et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997-5002.
12. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999;144: 281-292.
13. Li PF, Dietz R, von Harsdorf R. P53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999;18: 6027-6036.
14. Stennicke HR, Jurgensmeier JM, Shin H, et al. Procaspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998;273:27084-27090.
15. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995;377:446-448.
16. Darmon AJ, Ley TJ, Nicholson DW, et al. Cleavage of CPP32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation. J Biol Chem 1996;271:21709-21712.
17. Andrade F, Roy S, Nicholson D, et al. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998;8:451-460.
18. Heibein JA, Goping IS, Barry M, et al. Granzyme B-mediated cytochrome c release is regulated by the bcl-2 family members bid and Bax. J Exp Med 2000; 192:1391-1402.
19. Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000;192:1403-1414.
20. Alimonti JB, Shi L, Baijal PK, et al. Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition. J Biol Chem 2001;276:6974-6982.
21. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors, 5th edn. UICC: Geneva, Switzerland, 1997.
22. Shanmugaratnam K (ed). Histologic Typing of Tumours of the Upper Respiratory Tract and Ear, 2nd edn. Springer Verlag: Berlin, 1991, 201pp.
23. Dukers DF, Oudejans JJ, Vos W, et al. Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. J Pathol 2002; 196:307-315.
24. Casciola-Rosen L, Nicholson DW, Chong T, et al. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med 1996;183:1957-1964.
25. Germain M, Affar EB, D'Amours D, et al. Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 1999;274:28379-28384.
26. Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187.
27. Robertson JD, Gogvadze V, Zhivotovsky B, et al. Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem 2000;275:32438-32443.
28. Vicat JM, Ardila-Osorio H, Khabir A, et al. Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor. Biochem Pharmacol 2003;65:423-433.
29. Tombolini V, De Sanctis V, Donato V, et al. Prognostic features and treatment outcome in patients with nasopharyngeal carcinoma: an experience of 20 years. Anticancer Res 2001;21:1413-1418.
30. Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys 2001;50:1181-1189.
31. Lee AWM, Foo W, Law SCK, et al. Staging of nasopharyngeal carcinoma: from Ho's to the new UICC system. Int J Cancer (Fred Oncol) 1999;84: 179-187.
32. Oudejans JJ, Harijadi H, Kummer JA, et al. High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol 2002;198:468-475.
33. Harn HJ, Hsieh HF, Ho LI, et al. Apoptosis in nasopharyngeal carcinoma as related to histopathological characteristics and clinical stage. Histopathology 1998;33:117-122.
34. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211.
35. Los M, Herr I, Friesen C, et al. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997;90:3118-3129.
36. Boesen-de Cock JG, Tepper AD, de Vries E, et al. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation. J Biol Chem 1999;274:14255-14261.
37. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002;62: 7316-7327.
38. Spruck III CH, Tsai YC, Huang DP, et al. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992;52:4787-4790.
39. Lung ML, Hu Y, Cheng Y, et al. p53 inactivating mutations in Chinese nasopharyngeal carcinomas. Cancer Lett 1998;133:89-94.
40. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
41. Huang H, Pan X, Zhou J. BHRF1 antisense oligonucleotide inhibits anti-apoptosis of nasopharyngeal carcinoma cells. Int J Mol Med 1999;4:649-653.
42. Homer D, Lewis M, Farrell PJ. Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV-related cancers. Intervirology 1995;38:195-205.
43. Hayes DP, Brink AA, Vervoort MB, et al. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol Pathol 1999;52:97-103.
44. Griffith TS, Anderson RD, Davidson BL, et al. Ratliff: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-2894.
45. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2 lignad selectively induces apoptosis and overcomes drug resistance in multipele myeloma: therapeutic applications. Blood 2001;98:795-804.
46. Sbih-Lammali F, Clausse B, Ardila-Osorio H, et al. Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 1999;59: 924-930.